» Articles » PMID: 17035340

The Secretion of HMGB1 is Required for the Migration of Maturing Dendritic Cells

Overview
Journal J Leukoc Biol
Date 2006 Oct 13
PMID 17035340
Citations 120
Authors
Affiliations
Soon will be listed here.
Abstract

Chemokines regulate the migration and the maturation of dendritic cells (DC) licensed by microbial constituents. We have recently found that the function of DC, including their ability to activate naïve, allogeneic CD4+ T cells, requires the autocrine/paracrine release of the nuclear protein high mobility group box 1 (HMGB1). We show here that human myeloid DC, which rapidly secrete upon maturation induction their own HMGB1, remodel their actin-based cytoskeleton, up-regulate the CCR7 and the CXCR4 chemokine receptors, and acquire the ability to migrate in response to chemokine receptor ligands. The events are apparently causally related: DC challenged with LPS in the presence of HMGB1-specific antibodies fail to up-regulate the expression of the CCR7 and CXCR4 receptors and to rearrange actin-rich structures. Moreover, DC matured in the presence of anti-HMGB1 antibodies fail to migrate in response to the CCR7 ligand CCL19 and to the CXCR4 ligand CXCL12. The blockade of receptor for advanced glycation end products (RAGE), the best-characterized membrane receptor for HMGB1, impinges as well on the up-regulation of chemokine receptors and on responsiveness to CCL19 and CXCL12. Our data suggest that the autocrine/paracrine release of HMGB1 and the integrity of the HMGB1/RAGE pathway are required for the migratory function of DC.

Citing Articles

Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy.

Wang Y, Liu C, Fang C, Peng Q, Qin W, Yan X Nanomicro Lett. 2024; 17(1):30.

PMID: 39347944 PMC: 11442722. DOI: 10.1007/s40820-024-01533-y.


Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.

Nelson A, McMullen N, Gebremeskel S, De Antueno R, MacKenzie D, Duncan R Breast Cancer Res. 2024; 26(1):78.

PMID: 38750591 PMC: 11094881. DOI: 10.1186/s13058-024-01818-5.


Multiple functions of HMGB1 in cancer.

Lv G, Yang M, Gai K, Jia Q, Wang Z, Wang B Front Oncol. 2024; 14:1384109.

PMID: 38725632 PMC: 11079206. DOI: 10.3389/fonc.2024.1384109.


Dual-Responsive Supramolecular Polymeric Nanomedicine for Self-Cascade Amplified Cancer Immunotherapy.

Hu W, Ye B, Yu G, Yang H, Wu H, Ding Y Adv Sci (Weinh). 2024; 11(20):e2305382.

PMID: 38493499 PMC: 11132052. DOI: 10.1002/advs.202305382.


Musashi-2 potentiates colorectal cancer immune infiltration by regulating the post-translational modifications of HMGB1 to promote DCs maturation and migration.

Meng X, Na R, Peng X, Li H, Ouyang W, Zhou W Cell Commun Signal. 2024; 22(1):117.

PMID: 38347600 PMC: 10863188. DOI: 10.1186/s12964-024-01495-z.